IceCure Medical's U.S. ProSense® active commercial install base for breast cancer cryoablation surged 70% since FDA marketing authorization in October 2025, reaching installations in major metros like New York, Los Angeles and Dallas. Clinical acceptance rose after ASBrS updated its Resource Guide to recommend cryoablation for low-risk patients.
IceCure's U.S. ProSense active commercial install base grew 70% following FDA marketing authorization in October 2025, driven by increased physician demand and significant lead generation at key medical society conferences. Installations expanded to clinics and hospitals across major metropolitan areas including New York, Los Angeles, Atlanta, Dallas and Detroit.
The American Society of Breast Surgeons updated its Resource Guide to recommend cryoablation as a treatment option for low-risk breast cancer patients, marking broader clinical acceptance. Additionally, ProSense received national media exposure via television segments on over 190 local stations, fueling patient awareness and inquiries.
IceCure is focused on expanding its footprint by providing training and education to physicians, targeting office-based treatment opportunities with its transportable, liquid-nitrogen-based ProSense system. The company aims to accelerate adoption through strategic conference engagement and partnerships to enhance market penetration.
